Published in Cancer Res on January 15, 2005
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol (2010) 3.01
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr Drug Targets (2006) 1.33
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A (2008) 1.33
Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res (2009) 1.33
Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med (2007) 1.23
Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. J Biol Chem (2008) 1.19
Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem Biophys Res Commun (2005) 1.18
JNK1 mediates degradation HIF-1alpha by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res (2010) 1.18
Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One (2009) 1.09
Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors. Phytochem Rev (2009) 1.08
Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer (2010) 1.06
Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res (2008) 1.05
Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem (2013) 1.03
Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol (2010) 1.02
Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg Med Chem Lett (2011) 1.01
Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J Med Chem (2011) 0.99
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer. Br J Cancer (2005) 0.97
Identification of Cys255 in HIF-1α as a novel site for development of covalent inhibitors of HIF-1α/ARNT PasB domain protein-protein interaction. Protein Sci (2012) 0.94
Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. Philos Trans R Soc Lond B Biol Sci (2014) 0.92
P14ARF inhibits human glioblastoma-induced angiogenesis by upregulating the expression of TIMP3. J Clin Invest (2012) 0.90
Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. Antimicrob Agents Chemother (2013) 0.90
A truncated Ah receptor blocks the hypoxia and estrogen receptor signaling pathways: a viable approach for breast cancer treatment. Mol Pharm (2006) 0.90
Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor. ACS Med Chem Lett (2012) 0.90
Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem (2008) 0.89
Inhibition of hypoxia-inducible factor-1alpha (HIF-1alpha) protein synthesis by DNA damage inducing agents. PLoS One (2010) 0.89
Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem (2012) 0.89
Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family. Br J Haematol (2008) 0.87
Inhibiting the hypoxia response for cancer therapy: the new kid on the block. Clin Cancer Res (2009) 0.87
KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS One (2012) 0.86
Hypoxia, stem cells and bone tumor. Cancer Lett (2011) 0.86
Constructing molecular complexity and diversity: total synthesis of natural products of biological and medicinal importance. Chem Soc Rev (2012) 0.84
HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers. PLoS One (2013) 0.84
P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway. Cancer Res (2014) 0.81
Inhibition of the HIF1α-p300 interaction by quinone- and indandione-mediated ejection of structural Zn(II). Eur J Med Chem (2014) 0.80
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. J Cell Biochem (2016) 0.78
Mitochondrial Energy Metabolism and Thyroid Cancers. Endocrinol Metab (Seoul) (2015) 0.76
Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway. Bioorg Med Chem Lett (2017) 0.75
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Structure of the novel ternary hydrides Li4Tt2D (Tt=Si and Ge). Acta Crystallogr B (2007) 10.58
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Natural mutagenesis of human genomes by endogenous retrotransposons. Cell (2010) 5.50
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res (2009) 4.81
An integrative approach for in silico glioma research. IEEE Trans Biomed Eng (2010) 4.55
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet (2012) 4.07
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol (2005) 3.42
Cytoplasmic domain structures of Kir2.1 and Kir3.1 show sites for modulating gating and rectification. Nat Neurosci (2005) 3.22
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol Cell (2003) 2.85
BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res (2008) 2.81
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Synthesis and anticancer activity of thiosemicarbazones. Bioorg Med Chem Lett (2006) 2.78
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol (2005) 2.74
Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol (2004) 2.71
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol (2007) 2.38
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol (2006) 2.37
Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med (2002) 2.34
The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. J Neurooncol (2014) 2.32
Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med (2007) 2.31
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res (2002) 2.27
The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol (2012) 2.24
Diagnosis of malignant glioma: role of neuropathology. J Neurooncol (2008) 2.23
A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A (2000) 2.20
The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 2.13
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity. Chem Biol (2005) 2.11
Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents (2005) 2.10
TARP subtypes differentially and dose-dependently control synaptic AMPA receptor gating. Neuron (2007) 2.07
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest (2004) 2.03
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.96
Arrowsmith two-node search interface: a tutorial on finding meaningful links between two disparate sets of articles in MEDLINE. Comput Methods Programs Biomed (2009) 1.96
Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain (2011) 1.95
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.94
Sympathetic innervation of the anterior left ventricular wall by the right and left stellate ganglia. Heart Rhythm (2012) 1.93
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J Exp Med (2005) 1.84
Implication of snoRNA U50 in human breast cancer. J Genet Genomics (2009) 1.80
A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov (2012) 1.77
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem (2010) 1.76
Genomic and proteomic analyses of the fungus Arthrobotrys oligospora provide insights into nematode-trap formation. PLoS Pathog (2011) 1.72
Inhibitor kappaB-alpha haplotype GTC is associated with susceptibility to acute respiratory distress syndrome in Caucasians. Crit Care Med (2007) 1.71
The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol (2009) 1.70
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin Cancer Res (2009) 1.70
Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One (2010) 1.70
Cancer susceptibility variants and the risk of adult glioma in a US case-control study. J Neurooncol (2011) 1.69
Mitomycin C-polyethylene glycol controlled-release film inhibits collagen secretion and induces apoptosis of fibroblasts in the early wound of a postlaminectomy rat model. Spine J (2010) 1.69
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Macroscopic, neat, single-walled carbon nanotube fibers. Science (2004) 1.67
Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res (2006) 1.67
Synthesis and biological properties of a 9,11-azo-prostanoid: highly active biochemical mimic of prostaglandin endoperoxides. Proc Natl Acad Sci U S A (1975) 1.64
Integrative, multimodal analysis of glioblastoma using TCGA molecular data, pathology images, and clinical outcomes. IEEE Trans Biomed Eng (2011) 1.63
The impact of the National Essential Medicines Policy on prescribing behaviours in primary care facilities in Hubei province of China. Health Policy Plan (2012) 1.63
SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet (2008) 1.62
Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science (1978) 1.62
New transmembrane AMPA receptor regulatory protein isoform, gamma-7, differentially regulates AMPA receptors. J Neurosci (2007) 1.62
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res (2002) 1.62
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene (2005) 1.61
Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol (2004) 1.61
The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist Updat (2003) 1.61
HIV prevalence and sexual risk behaviors among men who have sex with men: results from a statewide population-based survey in California. J Acquir Immune Defic Syndr (2006) 1.61
Aberrant methylation and down-regulation of TMS1/ASC in human glioblastoma. Am J Pathol (2004) 1.58
Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am Rev Respir Dis (1990) 1.58
Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene (2002) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther (2012) 1.55
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev (2002) 1.54
Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost (2013) 1.53
Hypoxia inducible factor-1: a novel target for cancer therapy. Anticancer Drugs (2005) 1.52
Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2. Proc Natl Acad Sci U S A (1980) 1.52
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene (2002) 1.52
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
PPM1H is a p27 phosphatase implicated in trastuzumab resistance. Cancer Discov (2011) 1.50
Regulation of bone formation and remodeling by G-protein-coupled receptor 48. Development (2009) 1.50
Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res (2005) 1.49
Electric power and synthesis gas co-generation from methane with zero waste gas emission. Angew Chem Int Ed Engl (2011) 1.49
Open biopsy in patients with acute progressive neurologic decline and absence of mass lesion. Neurology (2010) 1.49
Cardiac and renal prostaglandin I2. Biosynthesis and biological effects in isolated perfused rabbit tissues. J Clin Invest (1978) 1.48
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology (2010) 1.47
Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol (1979) 1.47
PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion. J Biol Chem (2004) 1.47
Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc Natl Acad Sci U S A (1979) 1.47
Selective binding site for [3H]prostacyclin on platelets. J Clin Invest (1979) 1.47
Anne O'Tate: A tool to support user-driven summarization, drill-down and browsing of PubMed search results. J Biomed Discov Collab (2008) 1.46
Chemical self-replication of palindromic duplex DNA. Nature (1994) 1.46
Interaction of epothilone analogs with the paclitaxel binding site: relationship between binding affinity, microtubule stabilization, and cytotoxicity. Chem Biol (2004) 1.46
Mapping the C. elegans noncoding transcriptome with a whole-genome tiling microarray. Genome Res (2007) 1.46
Heptamethine cyanine dyes with a large stokes shift and strong fluorescence: a paradigm for excited-state intramolecular charge transfer. J Am Chem Soc (2005) 1.45
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity. Biochemistry (2002) 1.45
Conformation of a water-soluble derivative of taxol in water by 2D-NMR spectroscopy. Chem Biol (1994) 1.44
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44